国产精品久久久久久永久牛牛,55国产福利在线视频,成人午夜精品视频在线观看

目錄產(chǎn)品 » 穩(wěn)定細(xì)胞系 » Human Recombinant κ-Opioid Receptor OPRK1 Stable Cell Line
CHO-K1/OPRK1/Gα15 Stable Cell Line

Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with U-50488 in CHO-K1/OPRK1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/OPRK1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of U-50488 on CHO-K1/OPRK1/Gα15 cells was 42.36 nM.

CHO-K1/OPRK1/Gα15 Stable Cell Line

Figure 1. U-50488-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/OPRK1/Gα15 cells. The cells were loaded with Calcium-4 (Cat. No. R8142; Molecular Devices) prior to stimulation with OPRK1 agonist, U-50488. The intracellular calcium change was measured by FLIPRTETRA. The relative fluorescent units (RFU) were recorded and normalized to plot against the log of the cumulative doses of U-50488 (mean ± SEM, n = 3). The EC50 of U-50488 on CHO-K1/OPRK1/Gα15 cells was 11.07 nM.

Notes:
EC50 value is calculated with four parameter logistic equation:
Y=Bottom + (Top-Bottom) / (1+10^ ((LogEC50-X)*Hill Slope))
X is the logarithm of concentration. Y is the response.
Y is RFU and starts at Bottom and goes to Top along a sigmoid curve.

CHO-K1/OPRK1/Gα15 Stable Cell Line

Recombinant CHO-K1 cells stably overexpress human opioid receptor kappa 1 (OPRK1) on the surface and contain high levels of G protein Gαi to couple with the receptor in downstream signaling pathways.
M00290
詢價(jià)

聯(lián)系我們
Product Description Recombinant CHO-K1 cells stably overexpress human opioid receptor kappa 1 (OPRK1) on the surface and contain high levels of G protein Gαi to couple with the receptor in downstream signaling pathways.
Culture Properties Adherent
Stability Stable through more than 16 passages with no significant changes in assay performance or expression profile.
Size Two vials of frozen cells (>1×106 per vial in 1 mL)
Storage Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received.

Culture Medium Ham’s F-12K (Kaighn’s), 10% FBS, 200 μg/ml Zeocin (Cat. No. R250-01, Life Technologies), 100 μg/ml Hygromycin B (Cat. No. 10687010, Life Technologies)
Complete Growth Medium Ham’s F-12K (Kaighn’s), 10% FBS
Freeze Medium-DATA 45% Ham’s F-12K (Kaighn’s) (Cat. No. 21127, Life Technologies), 45% FBS (Cat. No. 10099-141, Life Technologies), 10% DMSO (Cat. No. D2650, Sigma)

  • CHO-K1/OPRK1/Gα15 Stable Cell Line
  • CHO-K1/OPRK1/Gα15 Stable Cell Line

    Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with U-50488 in CHO-K1/OPRK1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/OPRK1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of U-50488 on CHO-K1/OPRK1/Gα15 cells was 42.36 nM.

  • CHO-K1/OPRK1/Gα15 Stable Cell Line
  • CHO-K1/OPRK1/Gα15 Stable Cell Line

    Figure 1. U-50488-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/OPRK1/Gα15 cells. The cells were loaded with Calcium-4 (Cat. No. R8142; Molecular Devices) prior to stimulation with OPRK1 agonist, U-50488. The intracellular calcium change was measured by FLIPRTETRA. The relative fluorescent units (RFU) were recorded and normalized to plot against the log of the cumulative doses of U-50488 (mean ± SEM, n = 3). The EC50 of U-50488 on CHO-K1/OPRK1/Gα15 cells was 11.07 nM.

    Notes:
    EC50 value is calculated with four parameter logistic equation:
    Y=Bottom + (Top-Bottom) / (1+10^ ((LogEC50-X)*Hill Slope))
    X is the logarithm of concentration. Y is the response.
    Y is RFU and starts at Bottom and goes to Top along a sigmoid curve.


For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.


喜歡新升級(jí)的網(wǎng)站嗎?

討厭

不喜歡

一般

喜歡

非常喜歡

*
    主站蜘蛛池模板: 麻阳| 安达市| 遵义县| 班玛县| 临颍县| 宣汉县| 泽州县| 大城县| 疏附县| 镇江市| 莱芜市| 德庆县| 莱西市| 抚远县| 华宁县| 太和县| 洮南市| 隆安县| 阿拉善盟| 丹巴县| 合肥市| 瑞金市| 桃园县| 江华| 北京市| 蕲春县| 唐河县| 金坛市| 铁力市| 巴楚县| 泸定县| 泸水县| 周宁县| 南江县| 喀什市| 汤原县| 合江县| 靖江市| 三江| 察隅县| 治多县|